Latest Ratios: P/E Ratio -26.1x · EV/EBITDA N/A · ROE -27.8%. (2022–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $2.1B | $1.2B | $615M | — | — |
| Enterprise Value | $2.0B | $1.1B | $566M | — | — |
| P/E Ratio → | -26.05 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 6.13 | 3.12 | 2.39 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -27.8% | -27.8% | -67.0% | — | — |
| ROA | -26.6% | -26.6% | -35.1% | -50.4% | -58.0% |
| ROIC | -29.3% | -29.3% | -96.9% | — | — |
| ROCE | -31.3% | -31.3% | -40.4% | -57.9% | -60.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.20 | -0.19 | — | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -68.88 |
Net cash position: cash ($75M) exceeds total debt ($596000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 24.62 | 24.62 | 24.19 | 21.26 | 12.89 |
| Quick Ratio | 24.62 | 24.62 | 24.19 | 21.26 | 12.89 |
| Cash Ratio | 24.12 | 24.12 | 23.72 | 20.55 | 12.38 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $37M | $33M | $32M | $32M |
Clinical trial execution dependency
Based on reported figures, MBX trades at a price-to-book ratio of 5.17, which suggests that investors are assigning a significant premium to the company's proprietary PEP platform rather than its current tangible asset base, a common valuation characteristic for clinical-stage biotechnology firms in the endocrine space.
The elevated P/B multiple relative to peers like PepGen indicates that the market is pricing in a high probability of success for the lead candidate, MBX 2109. Investors should monitor whether this valuation remains supported as the company approaches critical Phase 2 data readouts, as any clinical setback could lead to a rapid compression of this premium.
As reported in financial statements, MBX's ROIC has remained consistently negative, reaching -5.9% in 2026Q1, which highlights the company's current status as a capital-consuming entity that has yet to generate the operational returns necessary to offset its significant investment in clinical development and research infrastructure.
The persistent negative ROIC is a structural reality for a pre-revenue firm, reflecting the heavy deployment of capital into long-term R&D projects. This trend suggests that the company is currently in a value-destruction phase from a pure return-on-capital perspective, which is expected to continue until the PEP platform achieves commercial validation.
According to recent SEC filings, MBX's current ratio has fluctuated significantly, dropping from 32.95 in 2025Q3 to 30.79 in 2026Q1, which, while appearing high, masks the underlying reality of a rapidly depleting cash position as the company funds its intensive clinical trial pipeline.
The high current ratio is largely a function of the company's cash-heavy balance sheet following recent financing rounds, rather than operational working capital efficiency. Investors should be cautious, as this liquidity buffer is highly sensitive to the burn rate and may require further dilutive equity raises to sustain operations through the next major clinical milestone.
Financial analysts frequently misapply the price-to-book ratio to MBX, as this metric fails to account for the intangible value of the PEP platform's intellectual property, which is the primary driver of the company's future earning potential rather than its current, relatively small tangible asset base.
Relying on P/B for a pre-revenue biotech firm obscures the true risk-reward profile, as it ignores the binary nature of clinical trial outcomes. A more appropriate analytical framework would involve probability-weighted net present value (rNPV) models that specifically account for the clinical success rates of the endocrine pipeline rather than static balance sheet multiples.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MBX stock.
MBX Biosciences, Inc. Common Stock's current P/E ratio is -26.1x. This places it at the 50th percentile of its historical range.
MBX Biosciences, Inc. Common Stock's return on equity (ROE) is -27.8%. The historical average is -47.4%.
Based on historical data, MBX Biosciences, Inc. Common Stock is trading at a P/E of -26.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.